Security key
29286M105
enGene Therapeutics Inc. - Common Shares (ENGN)
CUSIP: 29286M105
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Shares
- Shares outstanding
- 67,034,251
- Total 13F shares
- 55,801,630
- Share change
- -2,927,337
- Total reported value
- $380,008,010
- Price per share
- $6.81
- Number of holders
- 59
- Value change
- -$36,332,966
- Number of buys
- 33
- Number of sells
- 24
Report period
Q1 2026
Institutions
59
Top holders
10
ENGN full security history
Previous quarter: Q4 2025
enGene Therapeutics Inc. SEC filings
enGene Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29286M105
Recent filing periods:
Top shareholders of ENGN - enGene Therapeutics Inc. - Common Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
|
Company |
10%
from 13D/G
|
5,869,076
|
$52,997,756 | — | 31 Dec 2025 | |
| Invus Global Management, LLC |
13D/G
|
Raymond Debbane |
7.8%
|
5,253,159
|
$35,511,355 | +$6,818,136 | 31 Mar 2026 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
7.1%
|
4,771,414
|
$39,984,449 | -$2,304,500 | 31 Dec 2025 | |
| Deep Track Capital, LP |
13F
13D/G
|
Company |
6.7%
from 13D/G
|
4,377,572
|
$39,529,475 | — | 31 Dec 2025 | |
| Fonds de solidarite des travailleurs et des travailleuses du Quebec |
3/4/5
13D/G
|
10%+ Owner |
4.5%
from 13D/G
|
3,036,153
|
$45,542,295 | — | 18 Apr 2024 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
3%
|
1,528,768
|
$6,115,072 | $0 | 31 Dec 2024 | |
| Kynam Capital Management, LP |
13F
13D/G
|
Company |
2.2%
from 13D/G
|
1,492,898
|
$13,480,869 | — | 31 Dec 2025 | |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
|
BVF PARTNERS L P/IL |
1.8%
|
945,402
|
$3,781,608 | -$8,424,148 | 27 Jan 2025 | |
| VR Adviser, LLC |
13F
|
Company |
7.1%
|
4,771,414
|
$43,085,868 | — | 31 Dec 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
6%
|
4,000,000
|
$36,120,000 | — | 31 Dec 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
5%
|
3,336,264
|
$30,126,464 | — | 31 Dec 2025 | |
| BRAIDWELL LP |
13F
|
Company |
4.7%
|
3,131,319
|
$28,275,811 | — | 31 Dec 2025 | |
| Nextech Invest, Ltd. |
13F
|
Company |
3.2%
|
2,124,943
|
$19,188,235 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2.8%
|
1,900,000
|
$17,109,500 | — | 31 Dec 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
2.7%
|
1,840,898
|
$16,623,309 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2.2%
|
1,499,520
|
$13,540,666 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
2.1%
|
1,388,000
|
$12,533,640 | — | 31 Dec 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
1.7%
|
1,142,982
|
$10,321,127 | — | 31 Dec 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.6%
|
1,055,000
|
$9,526,650 | — | 31 Dec 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
950,000
|
$8,578,500 | — | 31 Dec 2025 | |
| Omega Fund Management, LLC |
13F
|
Company |
1.3%
|
876,357
|
$7,913,504 | — | 31 Dec 2025 | |
| SR ONE CAPITAL MANAGEMENT, LP |
13F
|
Company |
1.1%
|
747,750
|
$6,752,183 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.1%
|
718,485
|
$6,487,919 | — | 31 Dec 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.96%
|
643,370
|
$5,809,631 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.84%
|
561,797
|
$5,073,027 | — | 31 Dec 2025 | |
| Eversept Partners, LP |
13F
|
Company |
0.68%
|
455,835
|
$4,116,190 | — | 31 Dec 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.53%
|
352,087
|
$3,179,346 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.51%
|
343,928
|
$3,105,670 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.45%
|
303,686
|
$2,742,285 | — | 31 Dec 2025 | |
| Monashee Investment Management LLC |
13F
|
Company |
0.44%
|
295,000
|
$2,663,850 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.37%
|
250,000
|
$2,257,500 | — | 31 Dec 2025 | |
| Elmind Capital, LP |
13F
|
Company |
0.31%
|
210,000
|
$1,896,300 | — | 31 Dec 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.24%
|
163,645
|
$1,477,714 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.24%
|
161,512
|
$1,458,453 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.22%
|
147,889
|
$1,335,438 | — | 31 Dec 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.11%
|
76,765
|
$693,188 | — | 31 Dec 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.1%
|
64,380
|
$581,000 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.08%
|
56,454
|
$509,780 | — | 31 Dec 2025 | |
| Quadrature Capital Ltd |
13F
|
Company |
0.07%
|
48,583
|
$438,704 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.05%
|
35,877
|
$323,969 | — | 31 Dec 2025 | |
| Virtus Investment Advisers, LLC |
13F
|
Company |
0.05%
|
31,445
|
$283,948 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.04%
|
30,085
|
$271,668 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.04%
|
29,018
|
$262,032 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.04%
|
25,383
|
$229,208 | — | 31 Dec 2025 | |
| Pale Fire Capital SE |
13F
|
Company |
0.04%
|
24,004
|
$216,756 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.04%
|
23,980
|
$216,539 | — | 31 Dec 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.04%
|
23,922
|
$216,016 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.03%
|
20,782
|
$187,661 | — | 31 Dec 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.03%
|
19,960
|
$180,239 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.03%
|
17,300
|
$156,219 | — | 31 Dec 2025 |
Institutional Holders of enGene Therapeutics Inc. - Common Shares (ENGN) as of Q1 2026
As of 31 Mar 2026,
enGene Therapeutics Inc. - Common Shares (ENGN) was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
55,801,630 shares.
The largest 10 holders included
FCPM III SERVICES B.V., PERCEPTIVE ADVISORS LLC, Siren, L.L.C., Venrock Adviser, LLC, Blue Owl Capital Holdings LP, Deep Track Capital, LP, BRAIDWELL LP, Nextech Invest, Ltd., Vestal Point Capital, LP, and MPM BIOIMPACT LLC.
This page lists
59
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
57
Q1 2026 holders
59
Holder diff
2
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.